Thermo Fisher Scientific is reportedly planning to divest portions of its diagnostics business, with an estimated value of around $4 billion. This strategic move aims to offload lower-growth assets and streamline the company’s portfolio, potentially attracting interest from private equity firms.
Biotech giant Thermo Fisher eyes $4 billion sale of diagnostics assets
Thermo Fisher Scientific, a leading biotechnology research firm, is exploring the sale of parts of its diagnostics unit. Reports indicate the company has engaged advisers to gauge private equity interest in these assets, including its microbiology division, which produces infectious disease testing equipment. The potential divestment is valued at approximately $4 billion.
Strategic realignment in a volatile market
This potential sale comes amidst a period of volatility within the healthcare sector, partly driven by investor concerns regarding federal spending on research. Thermo Fisher’s shares have seen a decline this year, mirroring trends observed in some rival companies. The move is seen as a strategic effort to optimise the company’s portfolio by shedding lower-growth segments.
Key takeaways
- Thermo Fisher Scientific is considering selling parts of its diagnostics business.
- The estimated value of the divestment is around $4 billion.
- The microbiology unit, which focuses on infectious disease testing, is among the assets being considered for sale.
- Advisers are currently engaging with private equity firms to assess potential buyer interest.
- The sale is not guaranteed, and Thermo Fisher may opt to retain the assets.
- This potential divestment follows Thermo Fisher’s recent acquisition of Solventum’s purification and filtration business for approximately $4.1 billion in cash.
Industry context and company performance
The broader healthcare industry has experienced fluctuations, with some companies, including Thermo Fisher, seeing their share prices affected. Despite this, Thermo Fisher reported a 1% year-over-year organic revenue growth in the first quarter, with Chairman, President, and CEO Marc N. Casper expressing pride in the company’s performance in a challenging macroeconomic environment. The potential sale aligns with a trend of strategic portfolio adjustments within the sector, as evidenced by other companies like Becton, Dickinson and Company (BD) also planning to separate parts of their life sciences businesses.
Sources
- Thermo Fisher plans to sell parts of diagnostics unit for $4 billion, FT reports, Reuters.
- Subscribe to read, Financial Times.
- Thermo Fisher Considers Selling Diagnostics Business, PYMNTS.com.
